Posted from: Thursday, July 02, 2015 - 11:05 AM - Present

Advisory Committee Recommend Approval of New Cholesterol Drugs

June 15, 2015 – Last week the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee reviewed two drugs, Praluent (alirocumab), manufactured by Sanofi/Regeneron followed by Repatha (evolocumab), manufactured by Amgen. These drugs are known as proprotein convertase subtilisin/kexin type 9 blockers (PCSK9 inhibitors), which are under FDA review to reduce low-density lipoprotein “bad” cholesterol (LDL-C). During the review which took two days, the committee’s focused on safety (e.g. very low LDL-C levels, neurocognitive effects, and diabetes risk) and the use of LDL-C as a surrogate marker of cardiovascular risk. They also emphasized that statin therapy should be maximized prior to adding a PCSK-9 inhibitor to the therapy.

The advisory committee recommended the approval of both Praluent and Repatha, with votes of 13-3 and 11-4, respectively.  The majority of members supported approval for use in patients with heterozygous familial hypercholesterolemia (HeFH), a genetic disorder that causes very high LDL-C levels. In a separate vote, the committee unanimously (15-0) supported approval of Repatha for use in patients with homozygous familial hypercholesterolemia (HoFH), another rare genetic disorder that results in extremely high blood levels of LDL-C.

The committee remained cautious however when it came to using PCSK-9 inhibitors in a broader population of patients with less risk until data from the cardiovascular outcomes trials becomes available in 2017. The FDA considers the recommendations of the advisory committee but does not have to agree with them. The PDUFA date for Praluent is July 24, 2015. Repatha’s Pdufa date is August 27, 2015.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Sunday, October 22, 2017 - 09:31 AM.